Format

Send to

Choose Destination
Anticancer Res. 2016 Aug;36(8):4267-71.

Non-small Cell Lung Cancer in South Wales: Are Exon 19 Deletions and L858R Different?

Author information

1
Velindre Cancer Centre, Cardiff, Wales, U.K. rhian.s.davies@wales.nhs.uk.
2
Institute of Cancer Genetics, Cardiff University, Cardiff, Wales, U.K.
3
Velindre Cancer Centre, Cardiff, Wales, U.K.

Abstract

BACKGROUND/AIM:

In advanced non-small cell lung cancer (NSCLC), the epidermal growth factor receptor (EGFR) mutations L858R and exon 19 deletion (del19) predict response to EGFR tyrosine kinase inhibitors (TKIs). Trials have suggested a differential response to the second-generation EGFR TKI afatinib in favour of del19. We investigated whether this differential response is observed in clinical practice.

MATERIALS AND METHODS:

Retrospective demographic, treatment and outcome data were collected on patients with: stage III/IV NSCLC and either del19 or L858R, receiving an EGFR TKI as first-line treatment.

RESULTS:

There was no significant difference in overall survival (OS) between del19 (648 days, 95% confidence interval (CI)=461-835) and L858R (813 days, 95%CI=387-1,238), (p=0.616), or in duration of therapy between del19 (365 days, 95% CI=192-538) and L858 (428 days, 95% CI=263-593), (p=0.928).

CONCLUSION:

Patients with exon del19 did not have a significantly longer OS with first-generation TKIs.

KEYWORDS:

EGFR mutation; L858R; NSCLC; advanced non-small cell lung cancer; exon 19 deletion

PMID:
27466542
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center